Showing 1 - 8 results of 8 for search 'Patrick C. Ma', query time: 0.04s Refine Results
  1. 1
    Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

    Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy by Zuan-Fu Lim, Patrick C. Ma

    Published 2019-12-01
    Get full text
    Article
  2. 2
    Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

    Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas by Bryan Oronsky, Patrick C. Ma, Daniel Morgensztern, Corey A. Carter

    Published 2017-12-01
    Get full text
    Article
  3. 3
    The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance

    The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance by Albina Kibirova, Malcolm D. Mattes, Matthew Smolkin, Patrick C. Ma

    Published 2019-10-01
    Get full text
    Article
  4. 4
    Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura

    Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura by James T. Boothe, G. Thomas Budd, Matthew B. Smolkin, Patrick C. Ma

    Published 2017-11-01
    Get full text
    Article
  5. 5
    Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?

    Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? by Heidar J. Albandar, Jacob Fuqua, Jasim M. Albandar, Salahuddin Safi, Samuel A. Merrill, Patrick C. Ma

    Published 2021-02-01
    Get full text
    Article
  6. 6
    Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

    Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma by Chan Shen, Rolfy A. Perez Holguin, Eric Schaefer, Shouhao Zhou, Chandra P. Belani, Patrick C. Ma, Michael F. Reed

    Published 2022-04-01
    Get full text
    Article
  7. 7
    Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma

    Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma by Rui Chen, Wenjia Xia, Siwei Wang, Youtao Xu, Zhifei Ma, Weizhang Xu, Erbao Zhang, Jie Wang, Tian Fang, Quan’an Zhang, Gaochao Dong, William Chi-shing Cho, Patrick C. Ma, Giovanni Brandi, Simona Tavolari, Peter Ujhazy, Giulio Metro, Helmut H. Popper, Rong Yin, Mantang Qiu, Lin Xu

    Published 2019-06-01
    Get full text
    Article
  8. 8
    Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing

    Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing by So Yeon Kim, MD, Jun Yin, MD, Stephen Bohlman, MD, PhD, Phillip Walker, PhD, Sanja Dacic, MD, PhD, Chul Kim, MD, Hina Khan, MD, Stephen V. Liu, MD, Patrick C. Ma, MD, Misako Nagasaka, MD, PhD, Karen L. Reckamp, MD, Jim Abraham, PhD, Dipesh Uprety, MD, Feng Wang, PhD, Joanne Xiu, PhD, Jian Zhang, PhD, Haiying Cheng, MD, PhD, Balazs Halmos, MD

    Published 2022-09-01
    Get full text
    Article

Search Tools: